Clinical Trials
438 trialsCOARC
University of Texas Southwestern Medical Center
ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer
ImmunityBio, Inc.
Shared Decision Making in Low Risk Prostate Cancer
Massachusetts General Hospital
PEM-PRO
IRCCS San Raffaele
TA-P-OLIM
University Hospital, Ghent
KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study
Kousai Bio Co., Ltd.
Immunotherapy Before and After Surgery
ImmunityBio, Inc.
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
ImmunityBio, Inc.
Robotic Telesurgery in Urology
Case Comprehensive Cancer Center
HARMONY
Hoosier Cancer Research Network
exBOND
CG Oncology, Inc.
Superman
Canisius-Wilhelmina Hospital
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
BOOST
Relmada Therapeutics, Inc.
RESCUE
Relmada Therapeutics, Inc.
PuraBond
The Royal Wolverhampton Hospitals NHS Trust
Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Patient Recall of Cancer Screening and Diagnosis
Case Comprehensive Cancer Center
PROTOMEN
University Hospital, Rouen
Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
University of Alabama at Birmingham
NeoPSMA
Novartis
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)
Duke University
HARRIER
Lantheus Medical Imaging
Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells
Oncology Institute of Southern Switzerland
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Northwestern University
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
Northwestern University
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
National Cancer Institute (NCI)
A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
University of Rochester
Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology
M.D. Anderson Cancer Center
REPRESENTATION
Latin American Cooperative Oncology Group
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
CHEMOPROST
Institut Bergonié
Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation Toxicity
DiaCarta, Inc.
PSMA Therapy and Immunotherapy in Kidney Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
M.D. Anderson Cancer Center
TALON
Duke University
AVENTURINE
BioNTech SE
iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma
City of Hope Medical Center
HRPCa-II
Assistance Publique - Hôpitaux de Paris
A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Hoffmann-La Roche
Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer
VA Office of Research and Development
Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery
Thomas Jefferson University
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
Thomas Jefferson University
KATANA E3M
Foresee Pharmaceuticals Co., Ltd.
KATANA E6M
Foresee Pharmaceuticals Co., Ltd.
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer
M.D. Anderson Cancer Center
18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer
IRCCS San Raffaele
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients.
Guangzhou Red Pine Medical Instrument Co., Ltd.